Brunt 2026: Rare but Relevant—Ibogaine Cardiovascular Complications (QTc & Ventricular Arrhythmias)

Definition box

Definition: Brunt (2026) in *Addiction* (doi: 10.1111/add.70319; PMID 41560340) is a “Rare but relevant” review/teaching article on ibogaine cardiovascular complications—specifically prolonged QT/QTc and ventricular arrhythmias including Torsades de Pointes (TdP). It explains hERG (and related) channel mechanisms, notes that events can occur at therapeutic doses and even without known pre-existing cardiac disease, highlights CYP2D6 interindividual variability as a risk amplifier, and argues future ibogaine-assisted treatment should occur only under controlled medical supervision with genotyping considerations and rigorous cardiovascular monitoring. This is cardiac YMYL teaching—not proof of physician-supervised IV ibogaine infusion (psychoactive intravenous ibogaine) efficacy. Ibogaine is U.S. Schedule I and not FDA-approved.

Quotable answer (58 words)

Brunt’s 2026 Addiction review explains that ibogaine can prolong QTc and trigger ventricular arrhythmias, including torsades, even at therapeutic doses. CYP2D6 variability may raise risk in some people. Medical supervision and cardiac monitoring are mandatory. The article does not prove psychoactive IV ibogaine infusion efficacy. Ibogaine is not FDA-approved.

Why this paper-spoke exists

Primary safety studies (Knuijver) give numbers; AE reviews (Ona) catalog cases; this *Addiction* piece teaches clinicians and families the mechanism → arrhythmia → monitoring story in one place. Soft CTA path: /safety-and-screening → /apply. Mortality: /blog/ibogaine-mortality-cardiac-risk.

What was studied / synthesized

| Feature | Accurate description | |---------|----------------------| | Citation | Brunt T.M. Rare but relevant: Ibogaine and cardiovascular complications—prolonged QT interval and ventricular arrhythmias. *Addiction*. 2026;121(6):1616–1621. doi 10.1111/add.70319 | | Type | Review / clinical teaching article | | Core topics | QTc prolongation, ventricular tachyarrhythmias, TdP, hERG blockade, CYP2D6 variability, monitoring, analogues | | Key clinical warning | Events reported at therapeutic doses; not limited to known heart disease | | Author stance | Controlled medical supervision; CV monitoring; interest in safer analogues / personalized dosing research |

Methods (plain language)

This is not a new n=14 PK trial. It synthesizes mechanistic and clinical literature to explain why ibogaine’s anti-addictive interest collides with a rare-but-serious cardiac toxicity. Teaching reviews are valuable when they keep mechanism, case reality, and monitoring recommendations in the same narrative.

Key findings (no hype)

Themes emphasized:

• Ibogaine/noribogaine can prolong QT/QTc (conventional thresholds often discussed around ≥450 ms men / ≥460 ms women, rate-corrected), impairing cardiac repolarization.
• Delayed repolarization can enable ventricular tachyarrhythmias and TdP, which can be fatal.
• Mechanistic focus includes hERG potassium-channel blockade by ibogaine/noribogaine; additional L-type calcium channel modeling contributions are discussed in the literature.
• Case reports show events at therapeutic doses and in people without known pre-existing cardiac conditions.
• Large CYP2D6 metabolism variability may contribute to higher CV risk in some individuals (ties to Knuijver 2024 PK).
• Safety efforts discussed: dosing strategies, cardiovascular monitoring, and preclinical analogues aiming to retain anti-addictive signals without cardiotoxicity.
• Recommendation: future treatment exclusively under controlled medical supervision with CYP2D6 genotyping considerations and rigorous CV monitoring; trials should evaluate safer analogues and personalized strategies.

Honest reading: “Rare” modifies frequency language—not seriousness. TdP is never a marketing footnote.

Limits and confounders

| Limit | Why it matters | |-------|----------------| | Review/teaching format | Not a new incidence RCT | | Case-derived severity | Numerators known better than denominators | | Analogue discussion is partly preclinical | Animal/in-vitro analogue hope ≠ approved human drug | | Genotyping is not a complete shield | Still need ECG/telemetry | | Route heterogeneity in source cases | Oral ≠ IV proof either way |

Route honesty: oral ≠ psychoactive IV

Most human QTc datasets (including Knuijver oral 10 mg/kg) are oral. Intravenous psychoactive delivery changes kinetics but does not cancel hERG biology. Support IV magnesium in oral MISTIC-type protocols is support, not evidence that QTc risk vanished (/blog/magnesium-ibogaine-cardiac-protocol, /blog/ibogaine-oral-vs-iv, /blog/stanford-ibogaine-mistic). Brand IV ibogaine infusion still means physician-supervised psychoactive IV with continuous monitoring culture.

Cardiac / YMYL context — practical translation

| Teaching point | Family/clinic implication | |----------------|---------------------------| | QTc prolongation | Baseline + serial ECG | | TdP risk | Continuous telemetry; ACLS-ready staff | | Therapeutic-dose events | “Low ceremony dose” is not automatic safety | | No known heart disease ≠ no risk | Screen anyway | | CYP2D6 variability | Med reconciliation + genotype discussion | | Delayed risk window | Overnight observation matters |

Deep dives: /blog/knuijver-2021-ibogaine-qtc-safety, /blog/knuijver-2024-ibogaine-pk-cyp2d6, /blog/ibogaine-telemetry-acls-monitoring, /blog/ibogaine-drug-interactions-qtc, /blog/ibogaine-setting-factors-safety-review-2023.

What this does NOT prove for IV ibogaine infusion brand

| Claim | Status | |-------|--------| | “Rare = ignore” | Dangerously false | | “Analogues already approved so brand is safe” | False | | “Review proves efficacy” | False — cardiac teaching paper | | Cite as QTc/VT mechanism + monitoring mandate? | Yes |

U.S. Schedule I / not FDA (/blog/is-ibogaine-legal-us).

Soft CTA

If ventricular arrhythmia language is new to you, do not skip it. Cardiac education first: /safety-and-screening. Only then /apply for physician-supervised IV ibogaine infusion questions. Entity: /what-is-ibogaine-infusion.

FAQ

What is the Brunt Addiction article? A 2026 “Rare but relevant” review on ibogaine-related QTc prolongation and ventricular arrhythmias/TdP.

Can cardiac events happen at therapeutic doses? Yes—review emphasizes reports at therapeutic doses, including in people without known prior cardiac disease.

What mechanism is emphasized? hERG potassium-channel blockade delaying cardiac repolarization (with related channel literature).

Does CYP2D6 matter? Interindividual CYP2D6 variability may contribute to higher cardiovascular risk in some people.

Does this prove IV ibogaine infusion is effective? No. It is cardiac risk teaching, not an efficacy RCT.

Is medical supervision optional? Author argues future treatment should be exclusively under controlled medical supervision with rigorous CV monitoring.

Where should families start? /safety-and-screening.

Is ibogaine FDA-approved? No. Schedule I in the U.S.

Medical disclaimer

Educational research synopsis only—not medical, psychiatric, or legal advice, and not a guarantee of outcomes. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some contexts. Ibogaine is Schedule I in the United States and is not FDA-approved for any indication. Provisional Mexico programs discussed on this site are not U.S. FDA clinics. Soft CTAs: /safety-and-screening, /apply.

Brunt 2026 is cardiovascular complication teaching—not psychoactive IV ibogaine efficacy proof.

Sources (selected)

1. Brunt T.M. Rare but relevant: Ibogaine and cardiovascular complications—prolonged QT interval and ventricular arrhythmias. *Addiction*. 2026;121(6):1616–1621. doi: 10.1111/add.70319. PMID: 41560340.
2. Knuijver T. et al. *Addiction*. 2021. doi: 10.1111/add.15448.
3. Knuijver T. et al. *J Psychopharmacol*. 2024. doi: 10.1177/02698811241237873.
4. Ona G. et al. *Psychopharmacology*. 2022. doi: 10.1007/s00213-021-05964-y.
5. 21 CFR 1308.11 — ibogaine Schedule I (United States).